ABSTRACT
Purpose: The main objective of this study is to explore the efficacy of olopatadine 0.1% treatment in the resolution of symptoms of vernal keratoconjunctivitis (VKC) among the Indian population. Methods: This single?center, prospective cohort study involved 234 patients with VKC. Patients were treated with olopatadine 0.1%, twice daily for a period of 12 weeks and then followed up in 1st week, 4th week, 3rd month, and 6th month. The extent of relief in the symptoms of VKC was measured using total ocular symptom score (TOSS) and ocular surface disease index (OSDI). Results: In the present study, the dropout rate was 5.6%. Total of 136 males and 85 females with a mean age of 37.68 ± 11.35 years completed the study. TOSS score reduced from 58.85 to 5.06 and the OSDI score reduced from 75.41 to 11.2 with statistical significance (P < 0.01) from 1st week to 6th week after olopatadine 0.1% treatment. The data showed relief in subjective symptoms of itching, tearing, and redness, and relief in discomfort in functions related to ocular grittiness, visuals like reading, and environmental like tolerability in dry conditions. Further, olopatadine 0.1% was effective in both males and females, and patients across ages 18–70 years. Conclusion: Based on TOSS and OSDI scores, the findings of this study validate safety and tolerability as revealed by low adverse effects and moderate efficacy of olopatadine 0.1% in reducing VKC symptoms in a broader age group (18–70 years) of both genders.
ABSTRACT
Background: Vernal keratoconjunctivitis (VKC) is a recurrent, bilateral, external, ocular inflammation primarily affecting young adults living in warm dry climates. The objectives of the research was to compare the two ophthalmic solutions of olopatadine hydrochloride (0.1%) and epinastine hydrochloride (0.05%) on clinical signs of vernal keratoconjuntivitis and to determine side effects of both the drugs.Methods: The study was carried out in 40 patients who attended the out-patient department (OPD) Ophthalmology, Darbhanga Medical College and Hospital, Laheriasarai from July 2007 to December 2008. Forty patients with symptoms of VKC (ocular itching, ropy discharge, papillary hypertrophy, gelatinous thickening and horner-trantas spots were selected and included in our study.Results: Mean score of palpebral hyperemia at 0, 14, 28 and 42 days in olopatadine treated eye were 2.1, 1.4, 0.8 and 0.4 respectively having p value <0.01, and <0.01 and <0.05 respectively, while mean score at same stages in placebo eye were 2.1, 2, 1.9, and 1.5 having value >0.05. Epinastine treated group mean score of palpebral hyperemia were <0.01 and <0.01 respectively in epinastine treated eye whereas in placebo treated eye, mean score were 2.1, 2.0, 1.8 and 1.6 respectively having p value >0.05 in all stages. Statistically insignificant reduction at day 14 while very significant reduction at day 28 and 42 was observed in epinastine treated eye as compared to placebo.Conclusions: The present study had shown that both olopatadine and epinastine were effective in treating clinical signs of VKC as compared to placebo.
ABSTRACT
Comparative evaluation of bepotastine besilate versus olopatadine and ketorolac combination onupper tarsal conjunctival brush cytology in patients of vernal keratoconjunctivitis. This studywas a prospective, open label, randomized, comparative clinical study. 100 patients of vernalkeratoconjunctivitis between 6 to 20 years of age of either sex willing to give informed consentwere enrolled in the study. In Group 1, 50 patients received Bepotastine besilate (0.15%) eyedrops twice daily for 8 weeks whereas in Group 2, 50 patients received Olopatadine (0.2%) andKetorolac (0.4%) combination eye drops twice daily for 8 weeks. Upper tarsal conjunctival brushcytology for eosinophil count was done in both the drug groups during the baseline and at 8th weekduring the treatment. It was found that after the 2 months of drug therapy, patients in both thegroups showed reduction in the eosinophil count. However, there was no statistically significantdifference between the two treatment groups at the baseline and at 8th week. There was 32%reduction in group A versus 28% reduction in group B in eosinophil count at the end of 8th weekcompared to baseline. Both bepotastine besilate versus olopatadine and Ketorolac combinationwere found to be effective in reducing the eosinophil count in patients of VKC.
ABSTRACT
Purpose: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic conjunctivitis cases. Hence, we decided to methodically study the efficacy of three topical medications. Methods: Prospective, observer-masked clinical trial enrolled 45 patients with 15 patients in each of the three groups. Patients with mild to moderate allergic conjunctivitis were sequentially assigned to respective groups, and relief of symptoms and signs were noted upto 1-month follow-up. Results: All three topical medications faired almost equally in resolving symptoms of the patients with mild to moderate allergic conjunctivitis, and most of them reported complete relief after 1 week of use of medication. Few cases with limbal or palpebral papillae reported symptomatic relief after use of medication, but the resolution of these signs was not noted in all three groups. Conclusion: We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis.
ABSTRACT
Ocular allergy is one of the most common disorders of the eye surface. Following diagnosis this condition is typically treated with preparations containing antihistamines. However, anatomy of the eye and its natural protective mechanisms create challenges for ocular drug delivery. Rapid elimination of antihistamine substances due to short residency times following application can lead to insufficient treatment of ocular allergies. With this in mind, the aim of this study was to prepare a controlled ocular delivery system to extend the retention time of olopatadine hydrochloride (OLO) and in doing so to reduce the need for frequent application. We developed extended-release ocular in situ gelling systems for which in vivo retention times were determined in sheep following in vitro characterization and cytotoxicity studies. In vivo results were then compared to commercially available Patanol eye drops. the transparent gels formulated using appropriate amounts of polymers and having longer ocular retention times appear to be a viable alternative to commercially available eye drops.
Subject(s)
Animals , Male , Female , In Vitro Techniques , Eye Diseases/pathology , Olopatadine Hydrochloride/adverse effects , Gelling Agents , Lubricant Eye Drops/pharmacokineticsABSTRACT
@#AIM: To observe the clinical efficacy of olopatadine eye drops combined with autologous serum in the treatment of artemisia pollen allergic conjunctivitis.<p>METHODS:Totally 305 patients with 610 eyes with allergic conjunctivitis and positive allergen test results of artemisia in our hospital were selected from June 2016 to June 2018, and randomly divided into the control group and the observation group. Patients in the control group were treated with olopatadine eye drops. Patients in the observation group were treated with autologous serum on the basis of the control group. Patients in both groups were treated continuously for 2wk. The total scores of symptoms and signs and clinical efficacy of the two groups were compared before and 2wk after treatment, and the adverse reactions during the treatment were observed. <p>RESULTS: Before treatment, there was no statistically significant difference in the total score of symptoms and signs between the two groups(<i>P</i>>0.05). Two weeks after treatment, the total score of symptoms and signs in the observation group was lower than that in the control group(<i>P</i><0.05), and the clinical efficacy of the observation group was better than that of the control group(<i>P</i><0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(<i>P</i>>0.05). <p>CONCLUSION: Olopatadine eye drops combined with autologous serum in the treatment of artemisia pollen allergic conjunctivitis has a definite clinical effect, which can effectively relieve the clinical symptoms and signs of patients with high security.
ABSTRACT
@#AIM:To systemically evaluate the clinical efficacy and safety of treating allergic conjunctivitis with olopatadine eye drops and other therapies. <p>METHODS: We performed a comprehensive search for the randomized controlled trials(RCTs)about the olopatadine eye drops and other therapies <i>vs.</i> olopatadine eye drops monotherapy for treating allergic conjunctivitis published by April, 2016 from PubMed, EMbase, Cochrane Library, VIP Chinese periodical Database, CNKI and Wan Fang Chinese periodical Database. Studies obtained from eligible database were filtered according to the criteria, and data were retrieved from those studies for further analysis. Then we performed a Meta-analysis using RevMan 5.3 software. <p>RESULTS: A total of 28 RCTs were included. Among all 3568 patients involved in, 1 799 were in the treatment group, while the other 1 769 were in the control group. The results of Meta-analysis showed that the olopatadine eye drops and other therapies was superior to monotherapy for patients with allergic conjunctivitis in clinical effects \〖<i>OR</i>=3.54,95%<i>CI</i>(2.71,4.61),<i>P</i><0.001\〗. <p>CONCLUSION: The existing evidence supports that the prognosis of the olopatadine eye drops and other therapies is better than olopatadine eye drops monotherapy for treating allergic conjunctivitis. For the quality and quantity limitations of the included studies, more well-designed and double blind RCTs are required to further prove this conclusion.
ABSTRACT
Objective To evaluate the efficacy and safety of olopatadine hydrochloride for the treatment of chronic idiopathic urticaria (CIU). Methods A multicentre, double-blind, randomized, parallel-group, controlled clinical trial was conducted. A total of 144 patients with CIU from 3 research centers were enrolled into this study, and randomly and equally divided into a test group and a control group. The test group administrated olopatadine hydrochloride 5 mg twice a day for 28 consecutive days, while the control group administrated levocetirizine hydrochloride 5 mg in the forenoon and a placebo tablet of olopatadine hydrochloride 5 mg in the afternoon for 28 consecutive days. The symptom score reducing index(SSRI)served as the primary outcome, and global assessment score for efficacy and total response rates as the secondary outcome. Results Totally, 137 patients completed the trial, including 70 in the test group and 67 in the control group. As intention-to-treat analysis showed, there were no significant differences in the total response rate between the test group and control group on day 7 (64.29% (45/70)vs. 56.72%(38/67), P > 0.05), 14(82.86%(58/70)vs. 74.63%(50/67), P > 0.05), or 28(87.14%(61/70)vs. 77.61%(52/67), P >0.05)after start of treatment. The SSRI was significantly higher in the test group than in the control group after 4 weeks of treatment(82.67% ± 22.70% vs. 70.51% ± 32.07%, P 0.05), and adverse reactions mainly included lethargy, dry mouth, fatigue, etc. Conclusion Olopatadine hydrochloride is effective and safe for the treatment of CIU.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and ADR of Houttuynia cordata eye drops combined with Olopatadine eye drops in the treatment of allergic conjunctivitis. METHODS:160 eyes with allergic conjunctivitis were randomly divided into observation group and control group,with 80 eyes in each group. The control group was given olopatadine eye drops,and observa-tion group was additionally given H. cordata eye drops(medication interval>10 min)on the basis of control group. Both groups were treated for 14 days. Symptoms and signs of 2 groups were observed and scored before treatment and 14 d after treatment. Ef-fective rates of 2 groups were calculated,and the occurrance of ADR was observed. RESULTS:Compared with before treatment, symptoms and sings score of 2 groups were decreased,with statistical significance (P<0.01 or P<0.05);the decrease of two score in observation group were more significant than in control group,with statistical significance (P<0.05);effective rates of control group and observation group were 37.50%and 77.50%,with statistical significance(P<0.05). CONCLUSIONS:H. corda-ta eye drops combined with olopatadine eye drops can ameliorate clinical symptoms and signs of allergic conjunctivitis patients sig-nificantly,and improve therapeutic efficacies without obvious ADR.
ABSTRACT
PURPOSE: To evaluate the effect of olopatadine and ketotifen to stabilize mast cells using human umbilical cord blood-derived mast cells (hCBMCs). METHODS: Using cultured hCBMCs, we divided the cells into the Ketotifen fumarate treatment group, the Olopatadine hydrochloride treatment group, the positive control group, and the negative control group. The histamine release inhibition rate was then observed. RESULTS: Ketotifen and olopatadine both showed the highest inhibition rate of histamine release at a concentration of 10(-3.5)M (Ketotifen, 48% and Olopatadine, 62%). The histamine release inhibition rate of olopatadine was 28% at a concentration of 10(-5.5)M, but ketotifen demonstrated a low histamine release inhibition rate at the same concentration. Ketotifen and olopatadine showed no histamine release inhibition at concentrations of 10(-2)~10(-2.5)M, and 10(-6)M. CONCLUSIONS: Ketotifen and olopatadine demonstrated histamine inhibition in the concentration range of 10(-3) to 10(-5)M. Olopatadine showed a slightly stronger response than ketotifen in the inhibition of histamine release.
Subject(s)
Humans , Histamine , Histamine Release , Ketotifen , Mast Cells , Umbilical Cord , Olopatadine HydrochlorideABSTRACT
BACKGROUND: Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. Substance P (SP) levels are increased in tears of patients with allergic conjunctivitis. However, little is known about the regulation of SP release by anti-allergic ophthalmic solutions. OBJECTIVE: We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions. METHODS: Conjunctivitis was induced by subconjunctival injection of histamine or intravenous injection of ovalbumin in rats passively sensitized with anti-ovalbumin anti-serum. The releases of SP were determined in the conjunctiva and tears using rat antigen-induced conjunctivitis models. RESULTS: Olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine- or antigen-induced hyperpermeability. The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions. Moreover, olopatadine significantly inhibited the release of SP from the conjunctiva. CONCLUSION: These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.
Subject(s)
Animals , Humans , Rats , Conjunctiva , Conjunctival Diseases , Conjunctivitis , Conjunctivitis, Allergic , Histamine , Injections, Intravenous , Mast Cells , Olopatadine Hydrochloride , Ophthalmic Solutions , Ovalbumin , Receptors, Histamine H1 , Substance P , TearsABSTRACT
Objective To observe the effect of olopatadine in the treatment of allergic conjunctivitis.Methods 67 cases with allergic conjunctivitis were randomly divided into 2 groups.The observation group was given 0.1％ hydrochloride olopatadine eyedrop twice a day for 7 days,while the control group was given 2％ cromolyn sodium 4 times a day for 7 days.One hour,7 days,20 days after treatment,the changes of symptoms and the incidence of adverse reactions were observed.Results 7 days after treatment,the totsl effective rate of the observation group in treatment of eye itching,conjunctival hyperemia and conjunctiva nipple were 91.18％,91.18％ and 85.19％,better than that of the control group[ 72.7％,75.76％,85.19％ ( all P ＜ 0.05 ) ].Conclusion It's rapid onset long duration of action and high security that olopatadine in the treatment of allergic conjunctivits,and it was worthy to promote to be used in clinic.
ABSTRACT
Seasonal allergic conjunctivitis is an illness which decreases quality of life and is common in society. Pharmacoeconomic evaluation about seasonal alergic conjunctivitis has not been measured in Turkey. The aim of our study is to understand the cost-effective medicines which are used for seasonal allergic conjunctivitis with Turkish data. In our study, effectiveness data from randomized controlled trials done with fluorometholon, epinastin, olopatadin, emedastin and ketotifen were used. Different effectiveness data reported in the trials were reduced to one single dataset. For cost data, direct costs like drug cost and physician meetings were counted in the calculation. Incremental cost effectiveness analysis (ICER) was performed with effectiveness and cost data which were obtained. In cost analysis lowest treatment cost was established by fluorometholon (US$ 38.94) and followed by ketotifen (US$ 43.41),epinastine (US$ 43.60), olopatadine (US$ 44.05) and emedastine (US$ 44.92), respectively. When the drugs compared for incremental cost-effectiveness, emedastine was dominated by ketotifen and emedastine dominated by olopatadine; ketofien could be compared with fluorometholon and olopatadine. Turkish data obtained and analyzed were similar with the literature. Reimburstment foundations can feature preparations which contain olopatadin and epinastin in treatment protocols, in the light of obtained data.
ABSTRACT
BACKGROUND: The main symptoms of allergic rhinitis (AR) are sneezing, rhinorrhea and nasal obstruction. It was reported that the nasal skin temperature after intranasal administration of histamine or grass pollen rose. In patients with AR, the levels of nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) have increased in nasal fluids and mucosa. OBJECTIVE: The present study were to determine the temperature changes of the nose in rat allergic rhinitis model, and if olopatadine, an antiallergic agent with histamine H1 receptor antagonistic action, proved to be effective, were studied the productions of NGF and VEGF in nasal lavage fluids (NALF). In the present study, we used ovalbumin (OVA)-sensitized rats as an animal model of nasal allergy and examined the effects of olopatadine on the skin temperature of the nose area, and the productions of NGF and VEGF in NALF. METHODS: The temperature changes of the nose area were carried out with thermo tracer in rat passively sensitized with OVA antiserum. The numbers of sneezing episodes were counted and, NGF and VEGF levels in NALF were examined using the specific ELISA. RESULTS: In OVA-sensitized rats, the number of sneezing episodes increase and the nasal skin temperature rise were provoked after OVA challenge. The levels of NGF and VEGF in NALF also were increased. Olopatadine reduced the increased frequency of sneezing and the nasal skin temperature rise. It also inhibited the increased NGF and VEGF productions in NALF. CONCLUSION: The nasal skin temperature after OVA challenge rose even in OVA-sensitized rats. These results suggest that the suppression of the increased NGF and VEGF levels might partially be involved in the improvement of allergy-like behavior (sneezing and nasal skin temperature rise) by the treatment of olopatadine.
Subject(s)
Animals , Humans , Rats , Administration, Intranasal , Enzyme-Linked Immunosorbent Assay , Histamine , Hypersensitivity , Models, Animal , Mucous Membrane , Nasal Lavage Fluid , Nasal Obstruction , Nerve Growth Factor , Nose , Olopatadine Hydrochloride , Ovalbumin , Ovum , Poaceae , Pollen , Receptors, Histamine H1 , Rhinitis , Rhinitis, Allergic , Skin Temperature , Sneezing , Thermography , Vascular Endothelial Growth Factor AABSTRACT
Objective To observe curative effect of olopatadine in treatment of allergic conjunctivitis combined with frequently winking in children. Design Prospective case series. Participants Ninety seven children with frequently winking aged 3-12 years in Shanghai Eye and ENT Hospital. Methods According to the factor in causation of frequently winking (FW), 97 children were divided into allergic conjunctivitis (AC) group, trichiasis combined AC group, AC with tics group, trichiasis group, tics group and unknown cau-sation group after clinical examination. The first 3 groups with AC were treated with olopatadine 0.1% ophthalmic solution b.I.d.(n=35) and emedastine 0.05% ophthalmic solution was used q.I.d, in AC group as control(n=32). The patients were followed after 3 weeks and the extent of symptoms of FW was recorded. Main Outcome Measures Extent of the symptoms of FW. Result The effective rate of olopatadine in treating FW caused by AC or AC combined with other diseases was 80.43%. The effective rate in FW children caused mainly by AC was 82.86% which was higher than that of control drug emedastine (75.0%) (P=0.02). Seven cure cases were all in olopatadine treating group. Conclusion AC is the most common and main causative factor in FW children. Early use of olopatadine ophthalmic drop can effectively alleviate FW symptoms. (Ophthalmol CHN, 2009, 18: 272-274)
ABSTRACT
Objective To observe the clinical effect of eye drops of 0.1%olopatadine hydrochloride(patanol) and 0.05%FKS06 (tacrolimus) for treating severe vernal keratoconjunctivitis in children.Design Prospective case siries.Participants 62 cases(104 eyes) of severe vernal keratoconjunctivitis aged 3-14 years old.Methods We observed the symptoms and signs of severe vernal keratoconjunctivitis before and after the treatment of 0.1%olopatadine hydrochloride and 0.05%FKS06.We examined regularly the blood,liver and kidney functions for all patients during treatment.Main Outcome Measures Symptoms and signs.Results Following by 3- 34months,all patients were much better in different degree at 1 week than that before.The papillae were decreased and almost disappeared gradually at 1 month.The corneal lesions were cured rapidly in less than 2 weeks.2 cases(3.2%) complained a little disconfort just at the beginning.38 cases(61.3%) recurred from 2 weeks to 8 months after stopping the eye drops,and were controlled rapidly after reusing the eye drops.The blood routine and the biochemical functions of all patients were normal during treatment.Conclusions 0.1% olopatadine hydrochloride and 0.05%FKS06 have remarkable effects for alleviating symptoms and signs of severe vernal keratoconjunctivitis. The patients are comfortable and content with the treatment,and side effects are very few.